Solventum Corporation (NYSE:SOLV) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Solventum Corporation (NYSE:SOLV) have been given a consensus rating of “Moderate Buy” by the fourteen brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $84.25.

SOLV has been the topic of a number of research reports. Rothschild & Co Redburn initiated coverage on Solventum in a research note on Tuesday, March 24th. They set a “sell” rating and a $60.00 price target on the stock. Wall Street Zen downgraded Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Weiss Ratings raised Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 11th. KeyCorp increased their price objective on Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Finally, Stifel Nicolaus decreased their price objective on Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th.

Solventum Trading Up 0.8%

NYSE:SOLV opened at $74.14 on Friday. The stock’s 50 day moving average price is $74.03 and its 200 day moving average price is $74.71. The company has a market capitalization of $12.84 billion, a PE ratio of 9.09, a P/E/G ratio of 1.13 and a beta of 0.69. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. Solventum has a 52-week low of $62.38 and a 52-week high of $88.20.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. The firm had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The firm’s quarterly revenue was down 3.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, research analysts anticipate that Solventum will post 6.58 EPS for the current year.

Institutional Trading of Solventum

Hedge funds have recently added to or reduced their stakes in the stock. Hilltop National Bank lifted its holdings in shares of Solventum by 71.3% in the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after buying an additional 129 shares during the period. CrossGen Wealth LLC acquired a new stake in shares of Solventum in the 4th quarter valued at approximately $25,000. Measured Wealth Private Client Group LLC acquired a new stake in shares of Solventum in the 3rd quarter valued at approximately $25,000. JNBA Financial Advisors lifted its holdings in shares of Solventum by 205.4% in the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after buying an additional 228 shares during the period. Finally, CYBER HORNET ETFs LLC acquired a new stake in shares of Solventum in the 2nd quarter valued at approximately $28,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.